Free shipping on all orders over $ 500

Lersivirine

Cat. No. M3743
Lersivirine Structure
Synonym:

UK-453061

Size Price Availability Quantity
5mg USD 130  USD130 In stock
10mg USD 215  USD215 In stock
50mg USD 740  USD740 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Lersivirine is a potent enzyme inducer in rodents capable of inducing a number of hepatic enzymes including those involved in its own metabolism. Preclinically lersivirine has been associated with hepatocellular hypertrophy and thyroid gland follicular cell hypertrophy in rats, mice, and dogs. Lersivirine has therapeutic potential for HIV-infected individuals with viral strains resistant against first-line NNRTIs. However, no large, well-powered studies have been conducted so far, which assess noninferiority against established antiretroviral agents. Lersivirine 750 mg and 1,000 mg qd was associated with lower rates of viral suppression at week 24 and week 48 versus etravirine in patients with prior NNRTI use and evidence of NNRTI resistance. No new safety signals were detected.

Chemical Information
Molecular Weight 310.35
Formula C17H18N4O2
CAS Number 473921-12-9
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] DeJesus E, et al. HIV Clin Trials. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.

[2] Houle CD, et al. Toxicol Pathol. Effects of Lersivirine on Canine and Rodent Thyroid Function.

[3] Platten M, et al. Expert Opin Investig Drugs. Lersivirine - a new drug for HIV infection therapy.

[4] Vourvahis M, et al. Drug Alcohol Depend. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.

Related HIV Protease Products
Arg-Val-(Nle-p-nitro)-Phe-Glu-Ala-Nle-NH2

Arg-Val-(Nle-p-nitro)-Phe-Glu-Ala-Nle-NH2 is a fluorogenic substrate of HIV-1 protease.

Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2

Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 is a substrato peptídico of HIV-1 protease.

HIV-1, HIV-2 Protease Substrate

HIV-1, HIV-2 Protease Substrate is the substrate of HIV-1, HIV-2 protease.

HIV Protease Substrate IV

HIV Protease Substrate IV is a substrate of HIV protease.

Herpes virus inhibitor 2

Herpes virus inhibitor 2 is a herpes virus inhibitor and disrupts herpes virus ribonucleotide reductase quaternary structure.

  Catalog
Abmole Inhibitor Catalog




Keywords: Lersivirine, UK-453061 supplier, HIV Protease, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.